Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
about
Aquaporin 4 and neuromyelitis opticaNeuroimmunological Implications of AQP4 in AstrocytesThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesFuture perspectives in target-specific immunotherapies of myasthenia gravisApplications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseasesChallenges and opportunities in designing clinical trials for neuromyelitis opticaImmunology of neuromyelitis optica: a T cell-B cell collaborationMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesBiomarkers of treatment response in multiple sclerosisGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.Mechanisms of Autoantibody-Induced Pathology.Experimental models of neuromyelitis optica.Aquaporins: important but elusive drug targets.Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat modelSmall-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.Neuromyelitis optica IgG causes placental inflammation and fetal death.Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis opticaBiology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.The treatment of neuromyelitis optica.Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer modelAquaporins as diagnostic and therapeutic targets in cancer: how far we are?Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG.Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementiaComplement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arraysAcute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.
P2860
Q24613666-8EC3B199-8382-46C8-A2D9-BCB623F31198Q26741610-DA396424-CF1A-4F8B-9039-DE50BB9E622DQ26767391-26E0A5A9-7AF7-44E1-83FB-7B2C0FA8B078Q26776225-B9700911-10B8-47EB-84C9-0AD74C8DE32CQ26860077-0992AE5C-DFF0-4C8F-972B-F85E70A006B8Q26999708-F3B261AF-FD0A-48B2-99E7-A67E041242E9Q27016045-CC7402B3-C425-4F90-9F26-4180B25219B0Q28075974-12AF4F2D-1475-4866-8FDB-687386B69A96Q28245749-B4A568AA-0740-4B78-A0D2-D9AE2E686966Q28305094-504E905E-2FB8-4F0E-822B-7BF1E6C53142Q30276550-77F94B8F-C010-49DA-A9FD-B020E3E51771Q30577078-DC09DC50-9190-4CD2-9D14-F761961A7E66Q30610471-B28932BD-643F-4334-9C1B-19AE9386FDDFQ30785267-55749CDA-6426-4475-8A1F-DEBBE10E9E36Q30975717-589C649B-138D-42E5-8BF5-B6C6EB3D3EDFQ33681420-BBA3EBCC-47B0-4CAC-8265-FCE346F3A696Q33740580-51013507-62B9-41DF-9C86-58AD07F9B453Q33785380-54C344CD-6280-40E4-8512-224F1A2F30C0Q33792739-67764511-A40D-40AF-9E5B-59A74EE81786Q34142474-E66A1DBB-80EC-415A-8C75-C949937EB8BDQ34154265-AD20AEC1-6937-4ACD-9CC9-58400B7872A6Q34168084-6D575826-E396-4053-BA39-E9516BAD6D04Q34173376-D8124CBD-4CA3-4B02-BA75-74029CF86E68Q34235490-1B0F6CBA-3F16-47B4-B1D3-5BB044228FA4Q34338762-45F0CB74-8237-44BC-AD0D-7D06B96DE769Q34377212-6CAEDADC-7786-417A-8134-E3AD941F6BDBQ34399291-96FCC92E-553C-483F-98C4-64D41BEA7D03Q34497097-3AFC8FA0-B567-4016-80A0-7BA46F7E31DDQ34529121-FC1D917A-45CB-46BE-8DD8-1416CDA4336AQ34545836-C1E061A1-8D21-4EDA-9312-8546736A6F41Q35013113-118D1811-F042-4C8F-AA5A-03E9459700F1Q35052199-F6DDC255-425C-4FA8-A393-416725E7E1E2Q35242214-CF307B96-E0E4-4A01-AF89-C5EBB754B2AFQ35245970-D2C06603-3B52-4DCF-8AD5-E440F4BC82E7Q35583116-511B5353-E511-4097-BC0C-1F9E0BBB3825Q35868696-5CDB95ED-E76C-452E-BF37-D66F6E233C26Q35922319-60BD9D6B-9A75-489D-AC60-1F83665856A5Q36118869-12572F48-7858-44A9-85DB-E6F9EBFDE65BQ36347678-0785D4C4-E8D5-4F06-8BA1-0FA465A0FFAFQ36596808-EB86AFC1-B1F0-4306-9749-0F08B35DEB10
P2860
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@ast
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@en
type
label
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@ast
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@en
prefLabel
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@ast
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.
@en
P2093
P2860
P356
P1433
P1476
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica
@en
P2093
A S Verkman
Chiwah Lam
Jeffrey L Bennett
Lukmanee Tradtrantip
Puay-Wah Phuan
P2860
P304
P356
10.1002/ANA.22657
P577
2012-01-23T00:00:00Z